Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
Bilici A, Koca S, Karaagac M, Aydin SG, Eraslan E, Kaplan MA, Ocak B, Goksu SS, Paydas S, Akgul F, Derin S, Ergun Y, Yekeduz E, Erol C, Ozyukseler DT, Demiray AG, Karaca M, Guc ZG, Menekse S, Cinkir HY, Gumusay O, Sakin A, Ozkul O, Demir H, Erdem D, Besiroglu M, Unal OU, Acar R, Koral L, Sahin S, Sakalar T, Bahceci A, Ozveren A, Gunaydin UM, Seker MM, Sunar V, Dal P, Artac M, Turhal S. Bilici A, et al. Among authors: sakin a. J Cancer Res Clin Oncol. 2023 Sep;149(11):8243-8253. doi: 10.1007/s00432-023-04766-3. Epub 2023 Apr 17. J Cancer Res Clin Oncol. 2023. PMID: 37067546
Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder.
Erdem GU, Dogan M, Sakin A, Oruc Z, Yaman E, Yesil Cinkir H, Uysal M, Bozkurt O, Ozturk B, Aytekin A, Ozcelik M, Bahceci A, Cakiroglu U, Turhal S, Sahin S, Uncu D, Zengin N. Erdem GU, et al. Among authors: sakin a. Oncol Res Treat. 2018;41(4):220-225. doi: 10.1159/000486598. Epub 2018 Mar 21. Oncol Res Treat. 2018. PMID: 29558755 No abstract available.
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group. Esin E, et al. Among authors: sakin a. Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30. Cancer Chemother Pharmacol. 2019. PMID: 30377778
A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
Degirmencioglu S, Tanriverdi O, Menekse S, Dogan M, Hacıoglu B, Oktay E, Erdem D, Arpaci E, Uluc BO, Turhal S, Yilmaz M, Pilanci KN, Sakin A, Araz M, Cokmert S, Ozdemir O, Sen E, Nayir E. Degirmencioglu S, et al. Among authors: sakin a. J BUON. 2019 Jan-Feb;24(1):136-142. J BUON. 2019. PMID: 30941962 Free article.
Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study.
Kaplan MA, Ozaydin S, Yerlikaya H, Karaagac M, Gumus M, Cil T, Yalcintas Arslan Ü, Ozdemir N, Sakin A, Bilici M, Koca D, Uysal M, Dane F, Sever ÖN, Seker MM, Oruc Seker Z, Can MF, Geredeli C, Aksoy A, Pilanci KN, Ozturk Topcu T, Isikdogan A. Kaplan MA, et al. Among authors: sakin a. Oncol Res Treat. 2019;42(10):516-522. doi: 10.1159/000502120. Epub 2019 Aug 22. Oncol Res Treat. 2019. PMID: 31437835
97 results